You are here

  • Home
  • Online First
  • Direct oral anticoagulants for stroke prevention in device-detected AF

Article Text

Article menu
Download PDFPDF
DTB select
Direct oral anticoagulants for stroke prevention in device-detected AF

https://doi.org/10.1136/dtb.2024.000049

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Key learning points

    • The efficacy and safety of oral anticoagulation for patients with device-detected subclinical atrial fibrillation (AF) is unknown.

    • Meta-analysis of data from two randomised controlled trials assessed the effect of apixaban or edoxaban in people with device-detected subclinical AF.

    • Treatment with apixaban or edoxaban reduced the risk of ischaemic stroke from 3% to 2% but increased the risk of major bleeding from 3.2% to 4.8%.

    The results of a systematic review and meta-analysis of two randomised controlled trials suggest that patients with device-detected subclinical atrial fibrillation (AF) may not benefit from treatment with a direct oral anticoagulant to prevent stroke.1

    Overview

    The authors of a systematic review and meta-analysis included data from two randomised controlled trials that compared oral anticoagulant treatment with aspirin or placebo in people with AF detected by a pacemaker, implantable cardioverter defibrillator, cardiac …

    View Full Text

    Footnotes

    • Contributors DTB Team.

    • Provenance and peer review Commissioned; internally peer reviewed.